Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

@inproceedings{Zheng2015ClinicalDA,
  title={Clinical detection and categorization of uncommon and concomitant mutations involving BRAF},
  author={G Zheng and L. H. Tseng and Guoli Chen and Lisa M Haley and Peter P B Illei and Christopher D Gocke and James R. Eshleman and Ming-Tseh Lin},
  booktitle={BMC Cancer},
  year={2015}
}
Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF p.V600E mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activity for different mutants. In this study, we categorized BRAF mutations according to the reported mutant kinase activity. A total of 1027 lung cancer, colorectal cancer or melanoma specimens were submitted for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Similar Papers

Loading similar papers…